GENSCRIPT-BIOTECH
14.4.2021 07:32:13 CEST | Business Wire | Press release
GenScript Biotech (Netherlands) BV , a subsidiary of GenScript Biotech Corporation ("GenScript", Stock Code: 1548.HK), a world-leading biotechnology company, and IES Diagnostics, the Life Science division of IES Medical, a company based in Spain, announced they have signed an agreement for the exclusive distribution of the GenScript cPass™ SARS-CoV-2 Neutralization Antibody Detection Kit in Spain, Portugal, and Andorra.
The test measures the presence of neutralizing antibodies (NAbs) in patients recovering from COVID-19 or receiving a vaccine. It is the only U.S. FDA Emergency Use Authorized (EUA) serology test for neutralizing antibodies from recent and prior SARS-CoV-2 infections. The kit is also CE marked (Europe) and has received HSA provisional approval (Singapore), ANVISA in Brazil, ANMAT in Argentina and has recently received clearance from the Ministry of Health and Prevention (MOHAP) in the United Arab Emirates as a medical device.
"With this collaboration, IES Diagnostics and GenScript will join forces to serve the local community with our expertise and resources. Since the outbreak of the worldwide pandemic in 2020, our company has been committed to supporting the global community in fighting COVID-19 with a comprehensive portfolio to support therapeutics and vaccine research and development, and diagnostic tool development including the novel cPass kit," said Aaron Qian, the President of European Division of GenScript.
Hubert Thomassen, CEO of IES Medical, said, "We are honored to be working with GenScript, proud to provide the unique and highly innovative cPass kit to our society that will contribute decisively to the knowledge of the immune status and level of protection of both those who have suffered a SARS-CoV-2 infection and those citizens who have been or will be vaccinated. The cPass kit is an essential tool in the development of any therapy aimed at combating this pandemic and in the development of an international immunity passport that allows our society to resume a normal social and economic life."
About GenScript Biotech Corporation
GenScript Biotech Corporation (Stock Code: 1548.HK) is a global biotechnology group. Based on its leading gene synthesis technology, GenScript has developed four major platforms including the global cell therapy platform, the biologics contract development and manufacturing organization (CDMO) platform, the contract research organization (CRO) platform, and the industrial synthesis product platform. The company’s operations span over 100 countries and regions worldwide with legal entities located in the US, Mainland China, Hong Kong, China, Japan, Singapore, the Netherlands, and Ireland. GenScript provides premium, convenient, and reliable products, and services for over 100,000 customers.
For more information visit http://www.genscript.com .
About IES Diagnostics
IES Diagnostics is the LifeScience division of IES Medical. IES Medical has its headquarters in Bilbao and offices in Madrid and Barcelona. The company directly serves clients all over the Iberian peninsula. IES Medical has a long-standing reputation for providing innovative products that contribute to improving the health of society in the areas of Emergency Medicine, Woundcare, Respiratory, and Diagnostics. The overall objective of IES Medical is to provide innovation for better care,
For more information visit https://www.iesmedical.es/ .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210413006175/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Paris Outpaces London as Europe’s Top AI City, According to The Observer’s AI Cities Index20.10.2026 13:11:00 CEST | Press release
Paris has claimed Europe’s AI crown, ranking higher than London as the continent’s leading hub of AI excellence. Yet Europe is struggling to compete with cities across the US and Asia, whose AI hubs lead the global rankings. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261020799504/en/ The Observer AI Cities Index Top Ten Cities 2026 This is according to The Observer’s inaugural AI Cities Index: a first-of-its-kind report identifying which cities are leading the global AI race when it comes to originating, building, financing and integratingartificial intelligence (AI). The new ranking has scored 57 cities across 36 countries based on levels of AI investment (assessing public, private and procedural investments in AI), innovation (capturing breakthroughs in technology that are indicative of greater capacity for AI in the future) and implementation (the availability of the infrastructure, institutions and systems needed to
New Research from One Biosciences Shows Single-Cell Profiling Can Identify Which Ovarian Cancer Tumors are Predisposed to Chemotherapy Resistance20.10.2026 13:02:00 CEST | Press release
Researchers from French National Centre for Scientific Research (CNRS), Institut Curie, Sorbonne Université and One Biosciences show ovarian cancer tumor cells may be epigenetically primed to resist chemotherapyClinical single-cell profiling at diagnosis may enable more personalized treatment strategies in difficult-to-treat cancer One Biosciences today announced data showing some ovarian cancer tumor cells are predisposed to resist chemotherapy and single-cell profiling at diagnosis can identify tumor profiles that indicate which patients are likely to experience treatment failure, ultimately enabling more personalized treatment strategies. Researchers from One Biosciences, French National Centre for Scientific Research (CNRS), Institut Curie, and Sorbonne Université found that the cellular changes linked to the development of resistance to cytotoxic chemotherapy cannot be explained by DNA mutations alone: the functional and epigenetic state of tumor cells play a key role and initial
IDWS 2026 Brings the World Together to Accelerate the Deployment of Water Solutions20.10.2026 12:38:00 CEST | Press release
Jeddah is preparing to host the fifth edition of the Innovation Driven Water Sustainability Conference (IDWS 2026) from 14 to 16 December 2026. The conference aims to accelerate the transition of water solutions from research and development to real-world deployment, while connecting innovators with investors and end users to strengthen water security, improve service efficiency, and enhance the sustainability of water resources worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261020192877/en/ Main session from IDWS 2025 (Photo: AETOSWire) The conference will bring together experts, researchers, innovators, investors, and representatives of water-sector organisations from more than 140 countries. It will feature over 250 speakers and is expected to attract more than 10,000 participants, alongside an international exhibition showcasing more than 150 global brands. Eng. Tariq Al-Ghafari, Deputy president for innovatio
European Wealth Firms Build Private Markets Capability Faster Than They Communicate It, Peregrine Report Finds20.10.2026 10:15:00 CEST | Press release
Capability outpaces communication: 73% of the 30 firms show visible private markets engagement, yet only 40% have a dedicated landing page explaining it to clients Swiss private banks set the benchmark: 70% maintain dedicated private markets destinations, led by Julius Baer, UBP, Pictet and Lombard Odier Visibility is concentrated: five firms generate half of all wealth management media coverage, and alternatives just 7% Europe's leading wealth managers have built genuine private markets capability but most have yet to explain it to the clients they built it for, according to The Wealth 30, a new report from Peregrine Communications. The study analyses how 30 leading UK and European wealth managers and private banks position private markets. It concludes that communication, not product, is now the biggest barrier to differentiation in the wealth channel. Capability outpaces explanation 73% of the Wealth 30 engage in private markets yet only 40% operate a dedicated landing page explaini
Infobip and Yamaha Power Conversational Customer Engagement in Indonesia’s Automotive Sector20.10.2026 10:00:00 CEST | Press release
Global AI-first cloud communications platform Infobip strengthens its collaboration with Yamaha Indonesia Motor Manufacturing (YIMM) to transform customer engagement through WhatsApp-powered conversational experiences designed to drive stronger personalization and faster customer interactions. As Indonesia’s consumers increasingly adopt digital-first purchasing behaviors, Yamaha Indonesia is evolving how it connects with customers across the buying journey. Today’s motorcycle buyers often research products through Yamaha’s social media, websites, and video reviews on YouTube before visiting dealerships, raising expectations for brands to deliver fast, seamless, and highly personalized communication. For more than two years, Infobip has supported Yamaha Indonesia in building connected customer engagement strategies that integrate WhatsApp across the company’s wider digital ecosystem, including its websites, social media platforms, and customer touchpoints. The collaboration reflects the
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom